United States Patent 7,229,613 (Colesevelam): Scope and Claims Breakdown, Patent Landscape, and Generic-Entry Risk
Executive summary: U.S. Patent 7,229,613 claims a medical method: reducing serum glucose in humans with diabetes by administering colesevelam (or a pharmaceutically acceptable salt) in a therapeutically effective amount. Claim scope is narrow to the active ingredient identity (colesevelam) and the endpoint (serum glucose reduction), with an additional limitation in dependent claims that colesevelam/salt is the only active ingredient administered. For U.S. competitive strategy, the patent functions primarily as a method-of-use barrier for colesevelam-focused diabetes therapies rather than a formulation, device, or process barrier.
What is the exact claim scope of U.S. Patent 7,229,613 for colesevelam methods of reducing serum glucose?
Short answer: The patent covers methods of lowering serum glucose in diabetic humans by administering colesevelam or its pharmaceutically acceptable salts; dependent claims add “only active ingredient administered” and specify salt administration.
Claim 1: Core method-of-use coverage
Claim 1 reads, in substance:
- A method for reducing serum glucose levels in a human diabetic patient
- Administer a therapeutically effective amount of colesevelam or a pharmaceutically acceptable salt
- No additional limitations on co-therapies, dosing regimen specifics, severity, or formulation type
Scope implications
- Active-ingredient tethering: Coverage is tied to colesevelam as the therapeutic agent.
- Endpoint tethering: The method is anchored on a biological effect: reduced serum glucose.
- Regimen flexibility: “Therapeutically effective amount” is broad and usually read as encompassing a wide range of dosing schedules that achieve glucose-lowering.
Claim 2: “Only active ingredient administered” limitation
Claim 2 adds:
- Same method as claim 1
- Plus: colesevelam/salt is the only active ingredient administered
Scope implications
- This narrows the method to scenarios where the patient receives colesevelam as the sole pharmacologically active antidiabetic agent.
- It creates a practical design-around lever for combination therapies. If the patient is co-administered another active ingredient (even another glucose-lowering agent), the literal “only active ingredient” requirement can be avoided.
Claims 3 and 4: Salt specification
- Claim 3: claim 1 with the limitation that a pharmaceutically acceptable salt of colesevelam is administered.
- Claim 4: claim 2 with the limitation that a pharmaceutically acceptable salt is administered.
Scope implications
- “Salt” language generally broadens coverage to salts that satisfy “pharmaceutically acceptable” standards.
- In practice, the “salt” category can still be limited by what is actually disclosed and used commercially, but the claims themselves include salts categorically.
How do the dependencies in U.S. Patent 7,229,613 affect infringement risk for combination therapy vs monotherapy?
Short answer: Claim 2 is the key narrowing feature. Monotherapy-like use patterns are closer to infringement risk; combination regimens that include another active antidiabetic agent push conduct outside claim 2, and possibly outside claim 1 only if colesevelam is not administered “as the method” being practiced.
Monotherapy use patterns
- If a diabetic patient receives only colesevelam (or its salt) as the antidiabetic active and the use is aimed at reducing serum glucose, claim 2’s “only active ingredient” limitation becomes a central infringement question.
- Claim 1 is still implicated under any scenario where colesevelam is administered in a method directed to serum glucose reduction, even if claim 2 is avoided.
Combination therapy
- If patients receive colesevelam plus another antidiabetic active (e.g., insulin, metformin, sulfonylurea, GLP-1 receptor agonist, SGLT2 inhibitor), claim 2’s “only active ingredient” limitation is harder to satisfy.
- Claim 1 remains at risk because it does not require absence of other actives. However, proving direct infringement generally turns on what “method” is actually being practiced. In many enforcement contexts, the primary attack is on label-directed or usage-directed conduct.
Design-around logic
- The “only active ingredient” limitation creates a specific litigation lever: if a challenger can show the claimed method is not practiced as “only colesevelam,” claim 2 can be narrowed out.
- Claim 1 lacks that co-therapy exclusion, so the design-around primarily targets claim 2, not claim 1.
Does U.S. Patent 7,229,613 protect formulations, dosing regimens, or manufacturing methods?
Short answer: No. The claims are method-of-use claims focused on an administration act and a glucose-lowering endpoint. No formulation composition, manufacturing step, or device component appears in the provided claim set.
What is not claimed (based on the text provided)
- No protective scope for:
- tablet, powder, suspension, or dose-form composition
- particle size, coating, release profile, or excipient selection
- manufacturing process parameters
- device features
- specific titration schedules or maximum/minimum daily dose ranges
What is claimed
- A human therapeutic method:
- administration of colesevelam or a salt
- “therapeutically effective amount”
- intended biological effect: reduced serum glucose
What patents typically surround colesevelam for diabetes in the U.S. (mechanism, indications, salts, and adjunct therapies)?
Short answer: In the U.S. colesevelam ecosystem, the larger patent landscape is usually segmented into:
- active ingredient coverage (compound patents, if extant)
- formulation/composition patents (dose forms)
- indication or method-of-use patents (diabetes, hyperlipidemia)
- combination therapy patents (colesevelam plus other glucose-lowering actives)
- procedural process patents (polymer synthesis and purification)
However: you provided only the text of claims for U.S. 7,229,613, not the broader patent family, related continuations, or any bibliographic identifiers besides the patent number. A full landscape mapping would require citation-ready patent data, claim sets, and assignee records.
Given the constraint to produce only complete and accurate results, this analysis focuses on the scope that follows directly from the provided claims.
When does U.S. Patent 7,229,613 expire for exclusivity and patent term purposes in the U.S.?
Short answer: Not determinable from the claim text alone.
A patent’s U.S. expiration depends on:
- priority filing date
- patent term adjustment (PTA)
- statutory expiration under 35 U.S.C. § 154
- any terminal disclaimers
No filing/priority/issuance dates were provided for U.S. Patent 7,229,613 in the prompt. Without those bibliographic facts, an accurate expiration timeline cannot be stated.
What Orange Book status would U.S. Patent 7,229,613 have for generic competition of colesevelam?
Short answer: Not determinable from the claim text alone.
Orange Book listings depend on:
- whether the patent is listed for a specific drug product (NDC strength/form)
- whether the patent is treated as an “approved drug” use patent
- whether the patent covers method-of-use claims tied to an FDA-approved indication
- the listed claim type (e.g., use vs composition)
Without Orange Book entry data for the specific NDC(s) and patent linkage, the Orange Book status cannot be asserted accurately.
How would a Paragraph IV certification strategy likely frame U.S. Patent 7,229,613 in an ANDA for colesevelam?
Short answer: Because the claims are method-of-use, a Paragraph IV dispute would typically focus on whether the ANDA-labeled use practice infringes and/or whether the claims are invalid.
Likely infringement focus
- For claim 1: whether the accused product is administered at therapeutically effective amounts to diabetic patients to reduce serum glucose.
- For claim 2: whether the accused product is used as the only active ingredient administered.
Likely invalidity arguments (typical categories)
Even without asserting any outcome, method-of-use patents are often challenged on:
- lack of novelty or obviousness over prior art diabetes glucose-lowering teachings using colesevelam
- indefiniteness in how “therapeutically effective amount” or “serum glucose” endpoints are defined as applied
- non-infringement based on labeling and actual practice
This is strategy framing, not adjudication.
What generic-entry risks exist for colesevelam given the “only active ingredient” limitation in claim 2?
Short answer: The “only active ingredient administered” limitation creates a meaningful shield for combination regimens but does not remove risk under claim 1 if the method is still practiced with colesevelam as the relevant glucose-lowering intervention.
Practical risk split
- Monotherapy glucose-lowering use is closer to claim 2 exposure.
- Combination therapy weakens the claim 2 match but leaves claim 1 exposure depending on whether the accused conduct is treated as infringing the method claim.
Labeling and enforcement reality
Enforcement and infringement analyses in the U.S. often hinge on:
- FDA-approved labeling for the drug product
- promotional materials and instructions that drive patient use
- real-world prescribing patterns, to the extent they are attributable to the defendant
Your provided claims do not include method steps beyond “administer therapeutically effective amount,” so infringement is not limited to a complex protocol that might be avoided by regimen changes.
Does U.S. Patent 7,229,613 cover biosimilars or biologic substitutes?
Short answer: No, based on the claims provided.
- The claims recite colesevelam, which is a small-molecule/chemical therapeutic polymer (not a biologic).
- Biosimilar frameworks target biologics and biologic reference products under the BPCIA. A colesevelam method-of-use patent is conceptually orthogonal to biosimilar substitution.
How strong is the patent estate for colesevelam diabetes methods based solely on U.S. 7,229,613’s claim wording?
Short answer: The strength is structurally moderate for direct coverage of colesevelam-based glucose reduction, but it is limited by:
- lack of additional limiting features (which can cut both ways)
- absence of combination exclusions in claim 1
- a narrow dependent limitation in claim 2 that can be avoided in combination regimens
Strength drivers from the claims
- “colesevelam or a salt” narrows to a specific active ingredient
- “serum glucose levels” defines a pharmacodynamic endpoint
- “human diabetic patient” limits to the clinical population
Strength limiters from the claims
- The “therapeutically effective amount” and broad administration act can make validity contested on prior art dosing and expected effects.
- Claim 2’s “only active ingredient” can be avoided through co-therapy, reducing enforceable reach for combination-labeled or combination-practiced treatment.
Key Takeaways
- U.S. Patent 7,229,613 is a method-of-use patent limited to reducing serum glucose in human diabetic patients by administering colesevelam or a pharmaceutically acceptable salt.
- Claim 1 covers the glucose-lowering method using colesevelam without requiring absence of other active ingredients.
- Claim 2 narrows to scenarios where colesevelam/salt is the only active ingredient administered, making monotherapy use patterns closer to infringement risk.
- Claims 3-4 specify salt administration.
- The provided claim set does not support assertions about expiration dates, Orange Book listing status, family breadth, or litigation posture because those require bibliographic and FDA listing records not contained in the prompt.
FAQs
1) What does “therapeutically effective amount” mean in infringement analysis for U.S. 7,229,613?
It is a functional dosing threshold; infringement turns on whether the administered dose is sufficient to achieve the claimed glucose-lowering method in the patient population.
2) Does U.S. 7,229,613 require a specific diabetes type (Type 1 vs Type 2)?
The claim text provided states “human diabetic patient” without specifying a subtype.
3) Can a regimen with colesevelam plus another glucose-lowering drug infringe claim 2?
If another active ingredient is administered, it is less likely to satisfy the “only active ingredient administered” requirement of claim 2.
4) Does U.S. 7,229,613 cover colesevelam salts only, or also the free base/compound?
It covers colesevelam and pharmaceutically acceptable salts in the claim set provided.
5) Are formulation patents relevant to U.S. 7,229,613 based on the claim language provided?
Not from the claims provided; the coverage is method-of-use and does not recite formulation, composition, or manufacturing limitations.
References (APA)
No external sources were provided or cited in the prompt, and the necessary bibliographic and FDA/Orange Book records for U.S. Patent 7,229,613 were not included.
